Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
EGRX Eagle Pharmaceuticals, Inc. daily Stock Chart
EGRX [NASD]
Eagle Pharmaceuticals, Inc.
Healthcare | Drugs - Generic | USA
financial highlights | statements
Index- P/E21.67 EPS (ttm)2.05 Insider Own10.20% Shs Outstand14.63M Perf Week5.06%
Market Cap649.57M Forward P/E9.63 EPS next Y4.61 Insider Trans-2.07% Shs Float13.00M Perf Month2.49%
Income31.80M PEG72.23 EPS next Q1.16 Inst Own- Short Float21.76% Perf Quarter-27.25%
Sales204.00M P/S3.18 EPS this Y-29.80% Inst Trans0.09% Short Ratio10.72 Perf Half Y-47.05%
Book/sh12.93 P/B3.43 EPS next Y21.00% ROA10.70% Target Price54.00 Perf Year-24.64%
Cash/sh6.23 P/C7.12 EPS next 5Y0.30% ROE15.40% 52W Range36.03 - 85.66 Perf YTD10.20%
Dividend- P/FCF16.16 EPS past 5Y32.50% ROI24.90% 52W High-50.23% Beta1.77
Dividend %- Quick Ratio5.40 Sales past 5Y147.70% Gross Margin72.00% 52W Low18.31% ATR2.07
Employees108 Current Ratio5.60 Sales Q/Q-18.60% Oper. Margin15.30% RSI (14)50.19 Volatility5.06% 5.35%
OptionableYes Debt/Eq0.23 EPS Q/Q-7.40% Profit Margin13.90% Rel Volume1.20 Prev Close44.40
ShortableYes LT Debt/Eq0.20 EarningsFeb 25 BMO Payout0.00% Avg Volume263.98K Price42.63
Recom2.40 SMA205.00% SMA50-5.24% SMA200-31.44% Volume202,879 Change-3.99%
Nov-01-18Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-18Downgrade Piper Jaffray Overweight → Neutral
Mar-21-18Reiterated Mizuho Underperform $37 → $40
Nov-09-17Reiterated RBC Capital Mkts Outperform $81 → $75
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Jul-29-15Reiterated Piper Jaffray Overweight $94 → $119
Jan-04-19 06:51AM  Does Eagle Pharmaceuticals, Inc.s (NASDAQ:EGRX) CEO Pay Matter? Simply Wall St. +5.67%
Jan-02-19 07:00AM  Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-16-18 10:49PM  Hedge Funds Are Selling Eagle Pharmaceuticals Inc (EGRX) Insider Monkey
Nov-30-18 07:45AM  Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-27-18 06:50AM  Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS) Business Wire
Nov-26-18 09:05AM  Investors Are Undervaluing Eagle Pharmaceuticals Inc (NASDAQ:EGRX) By 28.8% Simply Wall St.
Nov-19-18 07:00AM  Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-16-18 04:32AM  Moving Average Crossover Alert: Eagle Pharmaceuticals (EGRX) Zacks
Nov-07-18 11:10AM  Edited Transcript of EGRX earnings conference call or presentation 1-Nov-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-01-18 10:41AM  Eagle Pharmaceuticals (EGRX) Q3 Earnings Match Estimates Zacks +6.07%
08:21AM  Eagle Pharmaceuticals: 3Q Earnings Snapshot Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results Business Wire
Oct-30-18 06:50AM  Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase as Part of New $150 Million Share Repurchase Authorization Business Wire -16.52%
06:45AM  Eagle Pharmaceuticals Announces Results of Study for Fulvestrant Business Wire
Oct-25-18 05:00PM  Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2018 Financial Results on November 1, 2018 Business Wire
Oct-23-18 07:25AM  Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-19-18 09:28AM  Is Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Attractive At Its Current PE Ratio? Simply Wall St.
Oct-03-18 07:00AM  Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure Business Wire
Sep-27-18 07:00AM  Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference Business Wire
Sep-26-18 04:30PM  Eagle Appoints David Pernock to Position of Chief Operating Officer Business Wire
Sep-11-18 10:41AM  Does Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Fall With The Market? Simply Wall St.
Sep-07-18 08:32AM  Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod Zacks
Sep-05-18 10:21AM  Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position Zacks
Sep-04-18 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 16th Annual Global Healthcare Conference Business Wire
Aug-30-18 07:00AM  Eagle Pharmaceuticals Concludes Enrollment of Second Safety and Efficacy Study at Hajj to Evaluate RYANODEX for Exertional Heat Stroke Business Wire -16.28%
Aug-28-18 07:30AM  Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-23-18 07:00AM  Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies Business Wire
Aug-22-18 09:02AM  Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA Business Wire
Aug-20-18 03:34PM  Edited Transcript of EGRX earnings conference call or presentation 7-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-07-18 08:15AM  Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates Zacks
07:09AM  Eagle Pharmaceuticals: 2Q Earnings Snapshot Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results Business Wire
06:30AM  Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 11:21AM  Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates Zacks
Aug-02-18 11:47AM  Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally Zacks
Jul-31-18 08:53AM  NuVasive (NUVA) in Focus: Stock Moves 6.02% Higher Zacks
Jul-30-18 09:30AM  Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-25-18 07:00AM  Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018 Business Wire
Jul-09-18 07:00AM  FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection) Business Wire
Jul-03-18 08:30AM  Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA Business Wire
Jun-29-18 07:30AM  Investor Expectations to Drive Momentum within Education Realty Trust, Eagle Pharmaceuticals, Boingo Wireless, United Parcel Service, Marathon Petroleum, and Coherent Discovering Underlying Factors of Influence GlobeNewswire
Jun-11-18 09:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:50AM  Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection) Business Wire
May-29-18 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June Business Wire
May-18-18 07:40AM  Wired News FDA Granted Approval to Eagle Pharmas Bendamustine Hydrochloride RTD Solution in a 500ml Admixture ACCESSWIRE
May-17-18 07:50AM  Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-16-18 06:50AM  Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture Business Wire
May-13-18 05:46AM  Edited Transcript of EGRX earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-10-18 07:11AM  Eagle Pharmaceuticals: 1Q Earnings Snapshot Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results Business Wire
May-02-18 05:11AM  New Strong Sell Stocks for May 2nd Zacks
May-01-18 04:30PM  Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018 Business Wire
Apr-30-18 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference Business Wire
Apr-16-18 07:00AM  Eagle Pharmaceuticals Vasopressin ANDA Accepted for Filing by the FDA Business Wire
Mar-27-18 08:30AM  Eagle Pharmaceuticals Announces New Patent for Eagle Biologics Business Wire
Mar-06-18 07:10AM  Blog Exposure - Mylan Plans to Launch Two New HIV Treatments in the US ACCESSWIRE
Mar-01-18 07:42AM  New Strong Sell Stocks for March 1st Zacks
Feb-27-18 10:55AM  Eagle Pharmaceuticals (EGRX) Q4 2017 Earnings Conference Call Transcript Motley Fool -6.30%
Feb-26-18 10:16PM  Edited Transcript of EGRX earnings conference call or presentation 26-Feb-18 1:30pm GMT Thomson Reuters StreetEvents -8.88%
08:10AM  Recent Analysis Shows Valmont Industries, Guidewire Software, Eagle Pharmaceuticals, Bojangles', INVESCO MORTGAGE CAPITAL INC, and Archrock Partners Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
07:35AM  Eagle Pharmaceuticals posts 4Q profit Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results Business Wire
06:00AM  Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 04:30PM  Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018 Business Wire +5.14%
Feb-12-18 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 2018 RBC Capital Markets Global Healthcare Conference Business Wire
Feb-07-18 07:30AM  Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX Business Wire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit +8.97%
06:50AM  Eagle Pharmaceuticals, Inc. to Present at 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-28-17 12:04PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:47AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-21-17 07:14AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : December 21, 2017 Capital Cube
Dec-19-17 08:00AM  Research Report Identifies 2U, AK Steel Holding, American Water Works, Urban Edge Properties, Guidewire Software, and Eagle Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Dec-15-17 07:13PM  Cramer's lightning round: Buy Cisco when it goes below $3... CNBC Videos
Dec-07-17 06:50AM  Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant Business Wire
Nov-27-17 08:05AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Nov-20-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-16-17 09:01PM  Barron's After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges Barrons.com
08:36PM  Edited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-15-17 08:06AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Nov-10-17 01:10PM  Eagle Pharmaceuticals, Inc. Value Analysis (NASDAQ:EGRX) : November 10, 2017 Capital Cube
Nov-09-17 07:21AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017 Capital Cube -7.21%
Nov-08-17 10:44AM  Eagle Pharmaceuticals posts 3Q profit Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results Business Wire
06:10AM  Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare Conference Business Wire
Oct-30-17 04:30PM  Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017 Business Wire -6.52%
Oct-27-17 04:44PM  Eagle Pharma gets tentative FDA approval for Lilly's Alimta version Reuters
03:14PM  FDA tentatively approves Eagle Pharma's cancer drug Reuters
03:02PM  Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute Business Wire
Oct-24-17 09:37AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017 Capital Cube
Oct-17-17 07:33AM  Eagle Pharmaceuticals Announces New Patent for RYANODEX Business Wire
Oct-15-17 12:00PM  3 Biotech Values in a Fully Valued Market TheStreet.com
Oct-13-17 10:44AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017 Capital Cube
Oct-11-17 08:23AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017 Capital Cube
Oct-02-17 10:49AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
Sep-28-17 04:21PM  Edited Transcript of EGRX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Sep-25-17 08:52AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017 Capital Cube
Sep-22-17 07:40AM  Corporate News Blog - Eagle Pharmas Licenses Japanese Rights to SymBio Pharma for Bendamustine HCl Ready-to-dilute and Rapid Infusion Injection Products ACCESSWIRE
Sep-20-17 06:50AM  Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited Business Wire
Sep-19-17 11:08PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2017 Capital Cube
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tarriff ScottCEOJan 03Sale39.2916,569651,0581,518,390Jan 04 09:22 PM
Tarriff ScottCEOJan 02Sale39.7115,000595,7051,534,959Jan 04 09:22 PM
Tarriff ScottCEOJun 28Option Exercise4.04124,804504,2081,549,959Jul 03 05:09 PM
Tarriff ScottCEOMar 30Option Exercise4.04113,104456,9401,483,050Apr 03 05:05 PM
FLAUM SANDER ADirectorMar 06Sale53.942,340126,22011,374Mar 07 04:16 PM
FLAUM SANDER ADirectorMar 05Option Exercise0.902,3402,10613,714Mar 07 04:16 PM
open in yahoo | open in reuters | open in google